ERBB2 and breast carcinoma: Functionalization of liposomes with a breast cancer targeting peptide (H6, YLFFVFER) as a targeting nanocarrier system (Figure 7) shows high efficiency since antitumor drugs were successfully delivered into human epidermal growth factor receptor 2 (HER2) positive breast cancer cells in both in vivo and ex vivo models [217].